Table 1 Baseline characteristics of patients
Characteristics | Rituximab (n = 106) | Obinutuzumab (n = 18) | P value |
|---|---|---|---|
Age | 0.562 | ||
< 70 | 63(59.4%) | 12(66.7%) | |
≥ 70 | 43(40.6%) | 6(33.3%) | |
Sex | 0.109 | ||
Male | 49(46.2%) | 6(33.3%) | |
Female | 57(53.8%) | 12(66.7%) | |
Smoking | 25(23.6%) | 5(27.8%) | 0.937 |
ECOG PS score | |||
<2 | 78(73.6%) | 14(77.8%) | 0.933 |
≥ 2 | 28(26.4%) | 4(22.2%) | |
Comorbidities | |||
Hypertension | 31(29.2%) | 3(16.7%) | 0.412 |
Diabetes | 18(17.0%) | 2(11.1%) | 0.780 |
Pulmonary comorbidity | 7(6.6%) | 1(5.6%) | 1.000 |
Cardiac comorbidity | 11(10.4%) | 1(5.6%) | 0.835 |
Fully vaccinated | 69(65.1%) | 12(66.7%) | 0.897 |
Histological subtype | < 0.001 | ||
Aggressive lymphoma | 92(86.8%) | 8(44.4%) | |
Indolent lymphoma | 14(13.2%) | 10(55.6%) | |
Relapse/refractory disease | 23(21.7%) | 4(22.2%) | 1.000 |
Disease status | 1.000 | ||
Remission | 85(80.2%) | 14(77.8%) | |
Stable or progressive disease | 21(19.8%) | 4(22.2%) | |
Anti-CD20 mAB within 3 months before COVID-19 wave | 61(57.5%) | 16(88.9%) | 0.011 |
Period between last antineoplastic therapy and COVID-19 wave, Months, Median(range) | 2.5(0.2–11.5) | 0.7(0.4–6.8) | 0.060 |
Bendamustine | 5(4.7%) | 4(22.2%) | 0.031 |